AdvanDx, Inc. Elects Former Roche Molecular Systems CEO, Heiner Dreismann, Ph.D., to its Board of Directors

  AdvanDx, Inc. Elects Former Roche Molecular Systems CEO, Heiner Dreismann,
  Ph.D., to its Board of Directors

Business Wire

BOSTON -- March 27, 2013

AdvanDx, Inc. announced today that Heiner Dreismann, Ph.D., has joined its
board of directors as an independent director.

“We are extremely pleased to welcome Heiner as the newest member of the
AdvanDx board of directors,” said Dennis H. Langer, M.D., J.D., Chairman and
Chief Executive Officer of AdvanDx. “Heiner brings an valuable industry
perspective as a director – he has both the breadth of experience throughout
the diagnostics industry that will help us expand our core business, as well
as a deep understanding of how to develop and commercialize novel molecular
diagnostics products for infectious diseases, where our business is focused
today. This expertise will provide us with unique insights that will assist us
in executing on our mission to develop market-leading, next-generation
molecular diagnostic products that make a difference for our customers and
their patients, both in the United States and internationally.”

Dr. Dreismann has had a distinguished career in the diagnostics industry, both
as a senior operating executive and as a director of both public and private
companies. Dr. Dreismann was an executive at the Roche group from 1985 to
2006, where he held several senior positions, including President and CEO of
Roche Molecular Systems and a member of Roche’s Global Diagnostic Executive
Committee. Dr. Dreismann currently serves as a director on the board of
directors of several public and private health care and diagnostic companies,
including Myriad Genetics, Inc. Dr. Dreismann earned an M.S. in Biology and
Ph.D. in Microbiology/Molecular Biology summa cum laude from Westfaelische
University (The University of Munster) in Germany.

About AdvanDx, Inc.

AdvanDx is a leading provider of rapid and accurate molecular diagnostic tests
for identification of pathogens that cause critical infections in hospitalized
patients. Our mission is to improve antibiotic decision-making and patient
outcomes while limiting unnecessary and inappropriate antibiotic use and
reducing healthcare costs.

AdvanDx employs a unique, Whole Cell Analysis (WCA) approach to pathogen
identification using our proprietary Peptide Nucleic Acid Fluorescence In Situ
Hybridization (PNA FISH®) technology platform. This technology enables fast
and highly accurate single cell analysis for bacterial species identification
in samples from patients with critical infections.

AdvanDx is the market leader in molecular testing of positive blood cultures
enabling clinical microbiology labs to report pathogen identification results
48 to 72 hours earlier than with conventional testing methods. When used by
physicians and pharmacists to ensure early, appropriate antibiotic therapy for
patients with bloodstream infections, including septicemia, AdvanDx’s PNA
FISH® tests have been shown in clinical studies to reduce mortality rates,
shorten the length of hospital stay, and lower hospital costs.


AdvanDx, Inc.
Roger D. Graham, Jr.
Chief Commercial Officer
Sam Brown Inc.
Mike Beyer 773-463-4211
Press spacebar to pause and continue. Press esc to stop.